Venture Map · Round
ARTHEx Biotech — Series B · €42M
Announced 2023-05-03 · Valencia · Biotech
Valencia-based clinical-stage biotech ARTHEx closed a €42M Series B led by Columbus Venture Partners to take ATX-01, an antimiR targeting microRNA-23b, into a Phase I/IIa trial for Myotonic Dystrophy Type 1. New investors EIC, Hadean Ventures and Sound Bioventures joined existing backers Invivo Capital, AdBio Partners and CDTI-Innvierte.
RoundSeries B
Amount€42M
LeadColumbus Venture Partners
Date2023-05-03
CityValencia
SectorBiotech
The company
Investors 7
CColumbus Venture Partners
columbusvp.com
AAdBio Partners
CCDTI Innvierte
www.cdti.es
EEuropean Innovation Council Fund
eic.ec.europa.eu
HHadean Ventures
IInvivo Capital
invivo.partners
SSound Bioventures